home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Overall Residual Risk Evaluation - Webinar By GlobalCompliancePanel

 
  February 16, 2011  
     
 


GlobalCompliancePanel, Online Training Webinar
2011-04-20


Overview: This presentation discusses practical methods of performing Overall Residual Risk Evaluation and methods for documenting the results of the evaluation activity. Overall Residual Risk Evaluation requires a cross-functional team to perform the evaluation, which will be an important part of this presentation.

Why you should attend: One of the most important Risk Management activities is the Overall Residual Risk Evaluation which occurs at the end of the development cycle to assure the product risk meets the risk acceptability criteria prior to issuing the Risk Management Report and release of the product.  Companies have not had methods in place to perform this activity, and although some information appears in ISO 14971, there is not sufficient guidance on how to perform Overall Residual Risk Evaluation.

Areas Covered in the Session:
  • Choosing the Evaluation Team
  • Determining the Evaluation Process
  • What documents should be part of the review?
  • Using the Risk Chart in the review
  • How to compare to the Risk Acceptability Criteria
  • Documenting the results of the Evaluation
Who will benefit:
  • Risk Managers
  • Project Managers
  • Quality Engineers
  • Regulatory Managers
  • Clinical Managers
 
 
Organized by: GlobalCompliancePanel
Invited Speakers:
During his 20 year career in medical devices, Mr. Bills has held a number of quality and regulatory affairs positions. Mr. Bills is ASQ Certified as Quality Engineer, Quality Auditor, and as Manager of Quality/ Organizational Improvement. He also holds a certificate as Regulatory Affairs Certified through the Regulatory Affairs Professionals Society, and a BS and Masters degree from the University of Cincinnati. Recently, Mr. Bills served as US Industry Co-chair of the Association for Advancement of Medical Instrumentation committee, QM/WG04, on application of risk management to medical devices and is a current member of this group. Mr. Bills has presented at training courses for the American Association of Medical Instrumentation (AAMI) in the area of risk management and quality systems. Currently, Mr. Bills is the Principal Consultant at Bilanx Consulting LLC in the area of medical device quality, regulatory, product liability and risk management.
 
Deadline for Abstracts: 2011-04-20
 
Registration: Price List:
Live : $245.00
Corporate live : $995.00
Recorded : $295.00
E-mail: webinars@GlobalCompliancePanel.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.